Science News
from research organizations

First patient enrolled in phase 1 study of orally delivered capsule to treat recurrent clostridium difficile infection

Date:
January 18, 2017
Source:
Mayo Clinic
Summary:
The first patient has now been enrolled in a new phase one study of a unfrozen oral capsule formulated to treat Clostridium difficile infection.
Share:
FULL STORY

Mayo Clinic announced that it has enrolled the first patient in a phase one study of a unfrozen oral capsule formulated to treat Clostridium difficile infection.

The capsule is formulated to rehabilitate the human gut microbioby delivering a broad spectrum of live microbes into the patient's intestinal tract. The gut microbiome hosts trillions of microbes that live in harmony with their human host and perform processes vital for health.

"New therapies are urgently needed to prevent recurrent C-diff, a debilitating, costly and potentially life-threatening infection," says Sahil Khanna, M.B.B.S., a gastroenterologist at Mayo Clinic and principal investigator on the study. He says the study will enroll approximately 20 patients in a prospective, two-arm, phase-one, safety assessment and dosing study at Mayo Clinic's Rochester campus.

"C-diff infections are an increasingly difficult-to-resolve intestinal infection that cause about 29,000 deaths annually in the U.S.," says Dr. Khanna.

Dr. Khanna says potential advantages to providing an oral capsule for treatment that is stable at room temperature include flexibility in dosing and at-home treatment. Currently, patients seeking treatment must travel to a medical center for a fecal transplant procedure that involves the placement of live microbes into the patient's body in a procedure similar to a colonoscopy.


Story Source:

Materials provided by Mayo Clinic. Original written by Joe Dangor. Note: Content may be edited for style and length.


Cite This Page:

Mayo Clinic. "First patient enrolled in phase 1 study of orally delivered capsule to treat recurrent clostridium difficile infection." ScienceDaily. ScienceDaily, 18 January 2017. <www.sciencedaily.com/releases/2017/01/170118145050.htm>.
Mayo Clinic. (2017, January 18). First patient enrolled in phase 1 study of orally delivered capsule to treat recurrent clostridium difficile infection. ScienceDaily. Retrieved May 8, 2017 from www.sciencedaily.com/releases/2017/01/170118145050.htm
Mayo Clinic. "First patient enrolled in phase 1 study of orally delivered capsule to treat recurrent clostridium difficile infection." ScienceDaily. www.sciencedaily.com/releases/2017/01/170118145050.htm (accessed May 8, 2017).